Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas.
Swallow MA, Micevic G, Zhou A, Carlson KR, Foss FM, Girardi M. Swallow MA, et al. Among authors: foss fm. Cancers (Basel). 2024 Sep 5;16(17):3087. doi: 10.3390/cancers16173087. Cancers (Basel). 2024. PMID: 39272944 Free PMC article. Review.
Adverse cardiovascular events in patients treated with mogamulizumab.
Kwan JM, Henry ML, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre LA. Kwan JM, et al. Among authors: foss f. Am Heart J Plus. 2021 Oct 6;9:100049. doi: 10.1016/j.ahjo.2021.100049. eCollection 2021 Sep. Am Heart J Plus. 2021. PMID: 38559371 Free PMC article.
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Foss FM, Kim YH, Prince HM, Akilov OE, Querfeld C, Seminario-Vidal L, Fisher DC, Kuzel TM, Yannakou CK, Geskin LJ, Feldman T, Sokol L, Allen PB, Dang NH, Cabanillas F, Wong HK, Ooi CE, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Foss FM, et al. J Clin Oncol. 2024 Dec 19:JCO2401549. doi: 10.1200/JCO-24-01549. Online ahead of print. J Clin Oncol. 2024. PMID: 39700456
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Iyer SP, et al. Among authors: foss fm. Lancet Oncol. 2025 Jan;26(1):110-122. doi: 10.1016/S1470-2045(24)00508-4. Epub 2024 Nov 29. Lancet Oncol. 2025. PMID: 39617017 Clinical Trial.
Supramolecular chemistry in solution and solid-gas interfaces: synthesis and photophysical properties of monocolor and bicolor fluorescent sensors for barium tagging in neutrinoless double beta decay.
Auria-Luna F, Foss FW Jr, Molina-Canteras J, Velazco-Cabral I, Marauri A, Larumbe A, Aparicio B, Vázquez JL, Alberro N, Arrastia I, Nacianceno VS, Colom A, Marcuello C, Jones BJP, Nygren D, Gómez-Cadenas JJ, Rogero C, Rivilla I, Cossío FP, The Next Collaboration. Auria-Luna F, et al. Among authors: foss fw jr. RSC Appl Interfaces. 2024 Nov 4. doi: 10.1039/d4lf00227j. Online ahead of print. RSC Appl Interfaces. 2024. PMID: 39554374 Free PMC article.
304 results